English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The right to information is of crucial importance for the end-user of pharmaceuticals to exercise their right of self-determination. In the Directive 2001/83/EC relating to pharmaceuticals for human use all the particulars that have to be on the labelling or in the package leaflet are stipulated and need to be transposed into national law.This contribution scrutinises first the implications that a correct implementation of the information rules entails for the legal position of the individual. Second, the conditions and consequences of a failed implementation will be equally assessed in order to evaluate the legal impact when the right to information is violated by the state or the marketing authorisation holder.

Pharmaceutical information: Does the Directive 2001/83/EC protect such a right for the end user?